美港探案2019-10-10 23:53
$达美航空(DAL)$ 跌逾3%,尽管Q3盈利超预期;$Ra Pharmaceuticals(RARX)$ 暴涨逾100%,UCB将以21亿美元收购前者;PG&E大跌30%,因破产法官允许Elliot提出重组计划;3B家居大涨22%,任命前塔吉特高管为新任CEO;$如涵(RUHN)$ 招股书被指误导投资人,在美一个月遭逾10宗集体诉讼。查看全文
chuminhua2019-10-10 21:11
$Ra Pharmaceuticals(RARX)$ $UCB(UCBJY)$ 10/10,UCB宣布以每股48美元,总计21亿美元现金收购Ra Pharma。前一天Ra Pharma的收盘价为22.70美元。Ra的C5抑制剂zilucoplan正在开展治疗重症肌无力(MG)的III期临床,该产品有望与Alexion的Soliris竞争。查看全文
英为财情Investing2019-10-10 20:43
$达美航空(DAL)$ 跌逾3%,尽管Q3盈利超预期;$Ra Pharmaceuticals(RARX)$ 暴涨逾100%,UCB将以21亿美元收购前者;PG&E大跌30%,因破产法官允许Elliot提出重组计划;3B家居大涨22%,任命前塔吉特高管为新任CEO;$如涵(RUHN)$ 招股书被指误导投资人,在美一个月遭逾10宗集体诉讼。查看全文
淘沙见金2019-10-10 18:42
$Ra Pharmaceuticals(RARX)$ EU pharma quite active in H2 so far on M&As
July: Boehringer Ingelheim / Amal Tx, Zambon / Breath Tx
Aug: Bayer / BlueRock Tx
Sept: Lundbeck / Alder Biopharma, SOBI / Dova Pharma
Oct: UCB / Ra Pharma
延续了最近欧洲药企来抄底的主查看全文
牛唐2019-03-16 14:58
$Akari Therapeutics(AKTX)$ FDA同意coversin在HSCT-TMA适应症的关键阶段的实验设计,引发了翻倍的增长,如果后续数据好的话,未来市值有望跟相$Ra Pharmaceuticals(RARX)$ 、$奥麦罗制药(OMER)$ 相比查看全文
淘沙见金2017-11-09 11:56
(个人笔记,欢迎讨论)
Apellis Pharmaceutical $Apellis Pharmaceuticals, Inc.(APLS)$ 是一家生物制药临床研发公司,头号在研药物APL2是补体分子C3抑制剂,用于治疗各种自身免疫性疾病如年龄相关性黄斑变性(AMD),PNH,自身免疫性溶血性贫血(Autoimmune hemolytic anemia,AIHA)和年龄相关...查看全文
$Ra Pharmaceuticals(RARX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-035491 Size: 12 KB 网页链接
$Ra Pharmaceuticals(RARX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-035492 Size: 4 KB 网页链接
$Ra Pharmaceuticals(RARX)$ 8-K Current report, items 1.01 and 9.01 Accession Number: 0001104659-20-033333 Act: 34 Size: 805 KB 网页链接
$Ra Pharmaceuticals(RARX)$ 8-K Current report, item 8.01 Accession Number: 0001104659-20-027201 Act: 34 Size: 22 KB 网页链接
$Ra Pharmaceuticals(RARX)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001047469-20-001072 Act: 34 Size: 6 MB 网页链接
$Ra Pharmaceuticals(RARX)$ 内部交易: 2020-02-18,Chief Medical Officer,Farzaneh-Far Ramin ,卖出,10595普通股, $46.61
$Ra Pharmaceuticals(RARX)$ 内部交易: 2020-02-18,Chief Medical Officer,Farzaneh-Far Ramin ,期权,10595普通股, $5.60
$Ra Pharmaceuticals(RARX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-023526 Size: 12 KB 网页链接
$Ra Pharmaceuticals(RARX)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000834237-20-008730 Act: 34 Size: 13 KB 网页链接
$Ra Pharmaceuticals(RARX)$ 内部交易: 2020-01-17,See Remarks,Ricardo Alonso ,卖出,2285普通股, $47.02